Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO1993019178) PEPTIDES UTILISES POUR L'INDUCTION DE TOLERANCE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

Claims

1. A composition comprising at least one peptide derived from a human T cell reactive feline
protein, said peptide selected from the group consisting of peptide X (SEQ ID NO: 7), peptide

Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9),
peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11), peptide C (SEQ ID NO: 12), peptide D (SEQ
ID NO: 13), and peptide E (SEQ ID NO: 14), each as shown in Figure 3.

2. The composition of claim 1 wherein the at least one peptide is selected from the group
consisting of peptide X (SEQ ID NO: 7), peptide

Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9),
peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11) and peptide E (SEQ ID NO: 14).

3. A composition of claim 2, wherein the
composition comprises peptide X (SEQ ID NO: 7).

4. A composition of claim 2, wherein the
composition comprises peptide Y (SEQ ID NO: 8).

5. A composition of claim 1, wherein said
composition comprises at least two peptides
selected from the group consisting of peptide X (SEQ ID NO: 7), peptide Y (SEQ ID NO: 8),
peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11) and peptide E
(SEQ ID NO: 14).

6. A composition of claim 5, wherein the
composition comprises peptide X (SEQ ID NO: 7) and peptide Y (SEQ ID NO: 8).

7. A therapeutic composition comprising a
pharmaceutically acceptable carrier or diluent and at least one peptide derived from a human T cell reactive feline protein, said peptide
selected from the group consisting of peptide X, peptide Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11), peptide C (SEQ ID NO: 12), peptide D
(SEQ ID NO: 13) and peptide E (SEQ ID NO: 14), each as shown in Figure 3.

8. A therapeutic composition of claim 7 wherein
said at least one peptide is selected from the group consisting of peptide X (SEQ ID NO: 7), peptide Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11) and peptide E (SEQ ID NO: 14).

9. A therapeutic composition of claim 8 wherein the composition comprises peptide X (SEQ ID NO: 7).

10. A therapeutic composition of claim 8 wherein the composition comprises peptide Y (SEQ ID NO: 8).

11. A therapeutic composition of claim 8 wherein
said composition comprises at least two peptides selected from the group consisting of peptide X (SEQ ID NO: 7), peptide Y (SEQ ID NO: 8),
peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11) and peptide E
(SEQ ID NO: 14).

12. A therapeutic composition of claim 11 wherein the composition comprises peptide X (SEQ ID NO: 7) and peptide Y (SEQ ID NO: 8).

13. A method of treating sensitivity to Felis
domesticus in an individual comprising
administering to the individual a
therapeutically effective amount of the
composition of claim 7.

14. A method of claim 13 wherein the therapeutic composition is administered subcutaneously.

15. A method of claim 13 wherein the therapeutic composition is administered in soluble form.

16. A method of treating sensitivity to Felis
domesticus in an individual comprising
administering to the individual a
therapeutically effective amount of the
composition of claim 8.

17. A method of claim 16 wherein the therapeutic composition is administered subcutaneously.

18. A method of claim 16 wherein the therapeutic composition is administered in soluble form.

19. A method of treating sensitivity to Felis
domesticus in an individual comprising
administering to the individual a
therapeutically effective amount of the
composition of claim 12.

20. A method of claim 19 wherein the therapeutic
composition is administered subcutaneously.

21. A method of claim 19 wherein the therapeutic
composition is administered in soluble form.

22. A method of treating sensitivity to Felis
domesticus in an individual comprising
administering to the individual a
therapeutically effective amount of at least two therapeutic compositions, each composition
comprising at least one peptide selected from the group consisting of peptide X (SEQ ID NO:
7), peptide Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B
(SEQ ID NO: 11) and peptide E (SEQ ID NO: 14), each peptide shown in Figure 3, said
compositions each comprising a pharmaceutically acceptable carrier or diluent.

23. A method of claim 22, wherein one of the
therapeutic compositions comprises peptide X
(SEQ ID NO: 7) and one of the therapeutic
compositions comprises peptide Y (SEQ ID NO: 8).

24. A method off claim 22 wherein each composition is administered in soluble form.

25. A therapeutic composition useful in treating a disease which involves an immune response to a protein antigen, said therapeutic composition comprising at least one peptide which comprises a sufficient percentage of the T cell epitopes of said protein antigen such that in a
substantial percentage of a population of
individuals sensitive to the protein antigen, the response of such individuals to the protein antigen is substantially diminished, with the proviso that the at least one peptide does not comprise the entire protein antigen.

26. The therapeutic composition of claim 25 wherein the response of the T cells of such individuals to said protein antigen is substantially
diminished.

27. The therapeutic composition of claim 25 wherein the protein antigen is an allergen.

28. The therapeutic composition of claim 25 wherein said therapeutic composition comprises at least two compositions.

29. A method of treating a disease which involves an immune response to a protein antigen comprising administering subcutaneously to a mammal a
therapeutic composition comprising a peptide
derived from the protein antigen and a
pharmaceutically acceptable carrier, in an
amount effective to tolerize T cells of the
mammal to the protein antigen, wherein the
peptide comprises at least one T cell epitope of the protein antigen.

30. A method of claim 29 wherein the mammal is a
human.

31. A method of claim 30 wherein the protein antigen is an allergen.

32. A method of claim 31 wherein the allergen is
from a genus selected from the group consisting of: the genus Dermatophagoides; the genus
Felis: the genus Ambrosia; the genus Lolium; the genus Cryptomeria; the genus Alternaria; the
genus Alder; the genus Betula: the genus
Ouercus; the genus Plea; the genus Artemisia;
the genus Plantago; the genus Parietaria: the genus Canis; the genus Blattella; the genus
Apis; and the genus Periplaneta.

33. A method of claim 32 wherein the allergen is selected from the group consisting of:
Per P I; Per f I; Per f II; Amb a I; Amb a II;
Lol p I; Lol p IX; Cry j I; and Cry j II.

34. A method of claim 31 wherein the peptide has minimal immunoglobulin E stimulating activity.

35. A method of claim 31 wherein the peptide binds immunoglobulin E to a substantially lesser
extent than protein allergen from which the
peptide is derived binds said immunoglobulin E.

36. A method of claim 31 wherein the peptide does not bind immunoglobulin E specific for the
protein allergen from which it is derived binds said immunoglobulin E, or if binding of the
peptide to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to said
protein allergen.

37. A method of claim 31 wherein the peptide is
selected from the group consisting of peptide X (SEQ ID NO: 7); peptide Y (SEQ NO: 8): peptide Z (SEQ ID NO: 9); peptide A (SEQ ID NO: 10);
peptide B (SEQ ID NO: 11); and peptide E (SEQ ID NO: 14), each peptide as shown in Fig. 3.

38. A method of claim 30 wherein the protein antigen is an autoantigen.

39. A method of claim 38 wherein the autoantigen is selected from the group consisting of: insulin; myelin basic protein; rh factor; acetylcholine receptors; thyroid cell receptors; basement
membrane proteins; thyroid proteins; PM-1;
glutamic acid decarboxylase (64K); and
carboxypeptidase H.

40. A method of claim 38 wherein the autoantigen is human myelin basic protein and the peptide
consists essentially of amino acid residues

41. A method of claim 38 wherein the autoantigen is human myelin basic protein and the peptide
consists essentially of amino acid residues
89-101 of human myelin basic protein.

42. A method of claim 38 wherein the autoantigen is human myelin basic protein and the peptide
consists essentially of amino acid residues
140-172 of human myelin basic protein.

43. A method of claim 38 wherein the autoantigen is human myelin basic protein and the peptide
consists essentially of amino acid residues
143-168 of human myelin basic protein.

44. A method of claim 30 wherein the composition is administered in soluble form.